- Numerous prominent investors of the earlier Sunstone funds also committed to the new fund.
- The investor base includes Vækstfonden, Danish Growth Capital II, the European Investment Fund (EIF), and the general partners of the fund.
Sunstone Life Science Ventures has reportedly announced the closure of its fourth life science venture fund, named Sunstone Life Science Ventures Fund IV, at about €80 million. As per trusted sources, the new fund would begin investing immediately.
Reportedly, the investor base of the venture includes Vækstfonden, Danish Growth Capital II, the European Investment Fund (EIF), and the general partners of the fund. Recent and notable exits from Sunstone Life Science Venture Fund III include Rigontec (purchased by MSD in 2017) and Prexton (tookover by H. Lundbeck last year), cited trusted sources.
Managing General Partner at Sunstone, Søren Lemonius was reportedly quoted saying that the successful closing of the new fund is a robust validation of the company’s strategy. Successful investment cases such as Prexton and Rigontec are prime examples of the strategy which can combine improved patient care and innovative science with superior returns to the company’s investors, Lemonius further added.
Reportedly, the investment team of the firm consists of veteran venture capital experts with access to a widespread network of scientific and industry leaders and are equipped with previous industry background. The team consists of Dr. Claus Andersson, General Partner, Dr. Sten Verland, General Partner, Peter Benson, Chairman & General Partner, and Søren Lemonius, Managing General Partner.
Peter Benson reportedly commented that the team of general partners is the key to the company’ success and it is quite unique that the present members have either worked with the team since the inception of Sunstone or are co-founders of the company. The team is proud of establishing Sunstone Life Science Ventures as one of the foremost European venture group over the past twelve years, Benson further added.